VXRT vs. BCRX

Last updated Apr 1, 2026

Compare and contrast key facts about Vaxart, Inc. (VXRT) and BioCryst Pharmaceuticals, Inc. (BCRX).

Performance

VXRT vs. BCRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vaxart, Inc. (VXRT) and BioCryst Pharmaceuticals, Inc. (BCRX). The values are adjusted to include any dividend payments, if applicable.

VXRT vs. BCRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
VXRT Vaxart, Inc.	74.65%	-47.68%	15.59%	-40.39%	-84.67%	9.81%	1,529.10%	-81.36%	-78.64%
BCRX BioCryst Pharmaceuticals, Inc.	22.05%	3.72%	25.54%	-47.82%	-17.11%	85.91%	115.94%	-57.25%	65.37%

Fundamentals

Market Cap VXRT : $139.36M BCRX : $2.09B
EPS VXRT : $0.07 BCRX : $1.20
PE Ratio VXRT : 8.49 BCRX : 7.93
PS Ratio VXRT : 0.58 BCRX : 2.39
Total Revenue (TTM) VXRT : $237.26M BCRX : $874.84M
Gross Profit (TTM) VXRT : $0.00 BCRX : $855.43M
EBITDA (TTM) VXRT : $18.07M BCRX : $345.49M

Returns By Period

In the year-to-date period, VXRT achieves a 74.65% return, which is significantly higher than BCRX's 22.05% return.

VXRT

• 1D: 0.83%
• 1M: -23.90%
• YTD: 74.65%
• 6M: 65.82%
• 1Y: 48.65%
• 3Y*: -7.19%
• 5Y*: -37.01%
• 10Y*: —

BCRX

• 1D: 0.74%
• 1M: 8.80%
• YTD: 22.05%
• 6M: 25.43%
• 1Y: 26.93%
• 3Y*: 4.51%
• 5Y*: -0.88%
• 10Y*: 12.90%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VXRT vs. BCRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VXRT

VXRT Risk / Return Rank: 62
VXRT Sharpe Ratio Rank: 57
VXRT Sortino Ratio Rank: 69
VXRT Omega Ratio Rank: 68
VXRT Calmar Ratio Rank: 59
VXRT Martin Ratio Rank: 54

BCRX

BCRX Risk / Return Rank: 57
BCRX Sharpe Ratio Rank: 61
BCRX Sortino Ratio Rank: 63
BCRX Omega Ratio Rank: 58
BCRX Calmar Ratio Rank: 53
BCRX Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VXRT vs. BCRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vaxart, Inc. (VXRT) and BioCryst Pharmaceuticals, Inc. (BCRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VXRT	BCRX	Difference
Sharpe ratio Return per unit of total volatility	0.43	0.53	-0.10
Sortino ratio Return per unit of downside risk	1.55	1.29	+0.27
Omega ratio Gain probability vs. loss probability	1.20	1.14	+0.06
Calmar ratio Return relative to maximum drawdown	0.76	0.48	+0.28
Martin ratio Return relative to average drawdown	1.21	0.77	+0.44
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VXRT vs. BCRX - Sharpe Ratio Comparison

The current VXRT Sharpe Ratio is 0.43, which is comparable to the BCRX Sharpe Ratio of 0.53. The chart below compares the historical Sharpe Ratios of VXRT and BCRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VXRT	BCRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.43	0.53	-0.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.39	-0.01	-0.37
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.18	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.22	0.01	-0.23

Correlation

The correlation between VXRT and BCRX is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VXRT vs. BCRX - Dividend Comparison

Neither VXRT nor BCRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VXRT vs. BCRX - Drawdown Comparison

The maximum VXRT drawdown since its inception was -98.71%, roughly equal to the maximum BCRX drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for VXRT and BCRX.

Drawdown Indicators

	VXRT	BCRX	Difference
Max Drawdown Largest peak-to-trough decline	-98.71%	-97.74%	-0.97%
Max Drawdown (1Y) Largest decline over 1 year	-57.26%	-44.24%	-13.02%
Max Drawdown (5Y) Largest decline over 5 years	-97.22%	-79.10%	-18.12%
Max Drawdown (10Y) Largest decline over 10 years	—	-83.69%	—
Current Drawdown Current decline from peak	-97.41%	-71.26%	-26.15%
Average Drawdown Average peak-to-trough decline	-82.63%	-69.63%	-13.00%
Ulcer Index Depth and duration of drawdowns from previous peaks	36.17%	27.45%	+8.72%

Volatility

VXRT vs. BCRX - Volatility Comparison

Vaxart, Inc. (VXRT) has a higher volatility of 27.15% compared to BioCryst Pharmaceuticals, Inc. (BCRX) at 15.92%. This indicates that VXRT's price experiences larger fluctuations and is considered to be riskier than BCRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VXRT	BCRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	27.15%	15.92%	+11.23%
Volatility (6M) Calculated over the trailing 6-month period	76.02%	34.22%	+41.80%
Volatility (1Y) Calculated over the trailing 1-year period	112.62%	50.81%	+61.81%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	96.15%	63.41%	+32.74%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	129.92%	72.94%	+56.98%

Financials